Observational studyFrontiers in endocrinology2025
How to enhance prediction of clinical outcomes in poor responders: integrating high-specific assays for anti-mullerian hormone with antral follicle count.
Observational study in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03826888 (Measurement of Different Anti-Müllerian Hormone Isoforms in Expected Poor Responders), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Measurement of Different Anti-Müllerian Hormone Isoforms in Expected Poor Responders: Does it Matter?
Who cites it
1 citing paper in PubMed.
- Development and validation of a clinical prediction model for poor ovarian response in assisted reproductive technology.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anti-Müllerian Hormone (AMH) and antral follicle count (AFC) are commonly used markers of ovarian reserve, yet their predictive accuracy in patients with low ovarian reserve remains limited. This study aimed to evaluate whether high-specific AMH assays targeting distinct molecular isoforms enhance the prediction of oocyte yield following ovarian stimulation (OS). Methods: A prospective observational study was conducted from February 2019 to December 2021 in a tertiary fertility center, including 72 women with low ovarian reserve (AMH <1.1ng/mL). On cycle day 2/3 before OS, Antral Follicle Count (AFC) and serum FSH, LH, estradiol, progesterone, and AMH levels were measured with the Elecsys assay (Roche). Frozen serum samples were analyzed with four high-specific AMH assays (AnshLabs, Texas): AL-196, AL-124, AL-105, and AL-133. Correlations were examined between AMH assays, AFC, and OS outcomes. Results: Patients' median age was 39 years, with AFC of 5.5 and median AMH-Elecsys of 0.64 ng/mL. All AMH assays correlated significantly with AFC and stimulation outcomes. The AL-196 assay showed the highest correlation with the number of follicles, cumulus-oocyte complexes (COCs), and metaphase II (MII) oocytes. Models combining AFC and AMH assays were strong predictors of COCs and MII oocytes, with AFC+AL-196 offering the best predictive value (Adjusted R2 = 0.474 for COCs and 0.485 for MII, p<0.001). Conclusion: High-specific AMH assays using linear-epitope antibodies improve the accuracy of predicting oocyte yield in women with low ovarian reserve, thereby enabling more precise counselling and supporting personalized ovarian stimulation strategies. Clinical trial registration: NCT03826888.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.